Abstract

We report nine children with relapsed (n = 8) or high-risk (n = 1) peripheral T-cell lymphoma (PTCL) who underwent autologous (n = 6) or allogeneic (n = 3) bone marrow transplantation (BMT). These children received transplants as part of a prospective phase I/II study of thioTEPA (TT) and total body irradiation (TBI) with escalating doses of VP-16. The median age of these patients at time of BMT was 6.5 years (range 2.5 years to 14 years). Three were transplanted with active disease after failing salvage chemotherapy. Of the other six, one was transplanted in first complete remission (CR) and five in second or subsequent CR. Of these nine patients, eight are free of disease a median of 25 months after BMT (range, 6 to 48 months), with an estimated 2-year relapse-free survival (RFS) of 89%. Six of these eight patients have been followed for 12 or more months after BMT, and in each their current remission exceeds their longest previous remission duration. The toxicity of the TT/TBI ± VP-16 regimens was significant but manageable, predominately consisting of severe mucositis. For a comparison, we reviewed retrospective data on the six additional children and adolescents with PTCL who underwent BMT during the 3-year period preceding this phase I/II study. The median age at BMT of these six patients was 19 years (range 15.5 years to 20 years). These patients were prepared for BMT with a variety of other regimens. One had no response to BMT and the other five relapsed at 1.5 to 5 months after BMT (median, 3 months) with an RFS of 0%. Our data suggest that thioTEPA plus TBI, with or without VP-16, is an effective preparative regimen for BMT for young patients with relapsed or high-stage PTCL and leads to prolonged RFS.

Original languageEnglish (US)
Pages (from-to)2938-2942
Number of pages5
JournalBlood
Volume80
Issue number11
StatePublished - Dec 1 1992

Fingerprint

Peripheral T-Cell Lymphoma
T-cells
Bone Marrow Transplantation
Bone
Thiotepa
Whole-Body Irradiation
Etoposide
Irradiation
Recurrence
Survival
Transplantation (surgical)
Salvaging
Transplants
Mucositis
Chemotherapy
Dosimetry
Toxicity

ASJC Scopus subject areas

  • Hematology

Cite this

Gordon, B. G., Warkentin, P. I., Weisenburger, D. D., Vose, J. M., Sanger, W. G., Strandjord, S. E., ... Coccia, P. F. (1992). Bone marrow transplantation for peripheral T-cell lymphoma in children and adolescents. Blood, 80(11), 2938-2942.

Bone marrow transplantation for peripheral T-cell lymphoma in children and adolescents. / Gordon, Bruce Geoffrey; Warkentin, Phyllis Irene; Weisenburger, Dennis D.; Vose, Julie Marie; Sanger, Warren G.; Strandjord, Sarah E.; Anderson, James R.; Verdirame, Joseph D.; Bierman, Philip Jay; Armitage, James Olen; Coccia, Peter F.

In: Blood, Vol. 80, No. 11, 01.12.1992, p. 2938-2942.

Research output: Contribution to journalArticle

Gordon, BG, Warkentin, PI, Weisenburger, DD, Vose, JM, Sanger, WG, Strandjord, SE, Anderson, JR, Verdirame, JD, Bierman, PJ, Armitage, JO & Coccia, PF 1992, 'Bone marrow transplantation for peripheral T-cell lymphoma in children and adolescents', Blood, vol. 80, no. 11, pp. 2938-2942.
Gordon BG, Warkentin PI, Weisenburger DD, Vose JM, Sanger WG, Strandjord SE et al. Bone marrow transplantation for peripheral T-cell lymphoma in children and adolescents. Blood. 1992 Dec 1;80(11):2938-2942.
Gordon, Bruce Geoffrey ; Warkentin, Phyllis Irene ; Weisenburger, Dennis D. ; Vose, Julie Marie ; Sanger, Warren G. ; Strandjord, Sarah E. ; Anderson, James R. ; Verdirame, Joseph D. ; Bierman, Philip Jay ; Armitage, James Olen ; Coccia, Peter F. / Bone marrow transplantation for peripheral T-cell lymphoma in children and adolescents. In: Blood. 1992 ; Vol. 80, No. 11. pp. 2938-2942.
@article{f934a1ab488e4025b0c6936ea5dc44d5,
title = "Bone marrow transplantation for peripheral T-cell lymphoma in children and adolescents",
abstract = "We report nine children with relapsed (n = 8) or high-risk (n = 1) peripheral T-cell lymphoma (PTCL) who underwent autologous (n = 6) or allogeneic (n = 3) bone marrow transplantation (BMT). These children received transplants as part of a prospective phase I/II study of thioTEPA (TT) and total body irradiation (TBI) with escalating doses of VP-16. The median age of these patients at time of BMT was 6.5 years (range 2.5 years to 14 years). Three were transplanted with active disease after failing salvage chemotherapy. Of the other six, one was transplanted in first complete remission (CR) and five in second or subsequent CR. Of these nine patients, eight are free of disease a median of 25 months after BMT (range, 6 to 48 months), with an estimated 2-year relapse-free survival (RFS) of 89{\%}. Six of these eight patients have been followed for 12 or more months after BMT, and in each their current remission exceeds their longest previous remission duration. The toxicity of the TT/TBI ± VP-16 regimens was significant but manageable, predominately consisting of severe mucositis. For a comparison, we reviewed retrospective data on the six additional children and adolescents with PTCL who underwent BMT during the 3-year period preceding this phase I/II study. The median age at BMT of these six patients was 19 years (range 15.5 years to 20 years). These patients were prepared for BMT with a variety of other regimens. One had no response to BMT and the other five relapsed at 1.5 to 5 months after BMT (median, 3 months) with an RFS of 0{\%}. Our data suggest that thioTEPA plus TBI, with or without VP-16, is an effective preparative regimen for BMT for young patients with relapsed or high-stage PTCL and leads to prolonged RFS.",
author = "Gordon, {Bruce Geoffrey} and Warkentin, {Phyllis Irene} and Weisenburger, {Dennis D.} and Vose, {Julie Marie} and Sanger, {Warren G.} and Strandjord, {Sarah E.} and Anderson, {James R.} and Verdirame, {Joseph D.} and Bierman, {Philip Jay} and Armitage, {James Olen} and Coccia, {Peter F.}",
year = "1992",
month = "12",
day = "1",
language = "English (US)",
volume = "80",
pages = "2938--2942",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "11",

}

TY - JOUR

T1 - Bone marrow transplantation for peripheral T-cell lymphoma in children and adolescents

AU - Gordon, Bruce Geoffrey

AU - Warkentin, Phyllis Irene

AU - Weisenburger, Dennis D.

AU - Vose, Julie Marie

AU - Sanger, Warren G.

AU - Strandjord, Sarah E.

AU - Anderson, James R.

AU - Verdirame, Joseph D.

AU - Bierman, Philip Jay

AU - Armitage, James Olen

AU - Coccia, Peter F.

PY - 1992/12/1

Y1 - 1992/12/1

N2 - We report nine children with relapsed (n = 8) or high-risk (n = 1) peripheral T-cell lymphoma (PTCL) who underwent autologous (n = 6) or allogeneic (n = 3) bone marrow transplantation (BMT). These children received transplants as part of a prospective phase I/II study of thioTEPA (TT) and total body irradiation (TBI) with escalating doses of VP-16. The median age of these patients at time of BMT was 6.5 years (range 2.5 years to 14 years). Three were transplanted with active disease after failing salvage chemotherapy. Of the other six, one was transplanted in first complete remission (CR) and five in second or subsequent CR. Of these nine patients, eight are free of disease a median of 25 months after BMT (range, 6 to 48 months), with an estimated 2-year relapse-free survival (RFS) of 89%. Six of these eight patients have been followed for 12 or more months after BMT, and in each their current remission exceeds their longest previous remission duration. The toxicity of the TT/TBI ± VP-16 regimens was significant but manageable, predominately consisting of severe mucositis. For a comparison, we reviewed retrospective data on the six additional children and adolescents with PTCL who underwent BMT during the 3-year period preceding this phase I/II study. The median age at BMT of these six patients was 19 years (range 15.5 years to 20 years). These patients were prepared for BMT with a variety of other regimens. One had no response to BMT and the other five relapsed at 1.5 to 5 months after BMT (median, 3 months) with an RFS of 0%. Our data suggest that thioTEPA plus TBI, with or without VP-16, is an effective preparative regimen for BMT for young patients with relapsed or high-stage PTCL and leads to prolonged RFS.

AB - We report nine children with relapsed (n = 8) or high-risk (n = 1) peripheral T-cell lymphoma (PTCL) who underwent autologous (n = 6) or allogeneic (n = 3) bone marrow transplantation (BMT). These children received transplants as part of a prospective phase I/II study of thioTEPA (TT) and total body irradiation (TBI) with escalating doses of VP-16. The median age of these patients at time of BMT was 6.5 years (range 2.5 years to 14 years). Three were transplanted with active disease after failing salvage chemotherapy. Of the other six, one was transplanted in first complete remission (CR) and five in second or subsequent CR. Of these nine patients, eight are free of disease a median of 25 months after BMT (range, 6 to 48 months), with an estimated 2-year relapse-free survival (RFS) of 89%. Six of these eight patients have been followed for 12 or more months after BMT, and in each their current remission exceeds their longest previous remission duration. The toxicity of the TT/TBI ± VP-16 regimens was significant but manageable, predominately consisting of severe mucositis. For a comparison, we reviewed retrospective data on the six additional children and adolescents with PTCL who underwent BMT during the 3-year period preceding this phase I/II study. The median age at BMT of these six patients was 19 years (range 15.5 years to 20 years). These patients were prepared for BMT with a variety of other regimens. One had no response to BMT and the other five relapsed at 1.5 to 5 months after BMT (median, 3 months) with an RFS of 0%. Our data suggest that thioTEPA plus TBI, with or without VP-16, is an effective preparative regimen for BMT for young patients with relapsed or high-stage PTCL and leads to prolonged RFS.

UR - http://www.scopus.com/inward/record.url?scp=0026475917&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026475917&partnerID=8YFLogxK

M3 - Article

VL - 80

SP - 2938

EP - 2942

JO - Blood

JF - Blood

SN - 0006-4971

IS - 11

ER -